Skip to content

Multisite Pacing With a Quadripolar Lead

Multisite Pacing With a Quadripolar Left Heart Lead in Cardiovascular Resynchronization Therapy (CRT) Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00964938
Enrollment
35
Registered
2009-08-25
Start date
2009-08-31
Completion date
Unknown
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Hemodynamic response, Cardiac resynchronization therapy

Brief summary

The purpose of this study is to evaluate the effects of multisite left ventricular (LV) biventricular (BiV) pacing on LV hemodynamics in CRT patients. It is hypothesized that the effect of simultaneous BiV pacing utilizing multisite LV pacing on LV hemodynamics will be superior to conventional BiV pacing.

Interventions

DEVICEQuadripolar LV lead (pacing configurations)

Quadripolar LV lead will be used to deliver a combination of pacing configurations

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have a scheduled CRT implantation at the participating clinical study site * Have NYHA functional class III or IV, ejection fraction less than or equal to 35%, and QRS duration greater than 120ms * Be undergoing a new St. Jude Medical CRT-D device system (including LV lead) implantation * Have the ability to provide informed consent for study participation and be willing and able to comply with the prescribed perioperative evaluations

Exclusion criteria

* Have persistent or permanent atrial fibrillation * Have an intrinsic heart rate of \<50 beats per minute * Have a recent myocardial infarction within 40 days prior to enrollment * Have undergone cardiac surgery or coronary revascularization procedure within 3 months prior to enrollment or be scheduled for such procedures * Have had a recent CVA or TIA within 3 months prior to enrollment * Have had intravenous inotropic support in the last 30 days * Have ischemic etiology and are unable to tolerate stress echocardiography

Design outcomes

Primary

MeasureTime frame
dP/dt maxacute: during implant procedure; 1 day

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026